“The zero-death figure is not a statistical artefact. It is what elimination looks like in the data.”
A generation of English women who received the HPV vaccine at school age are now in their early-to-mid thirties — and the cervical cancer deaths that population-level models predicted are not materialising. The Lancet analysis published today makes that concrete: in the highest-coverage birth cohort, the number of cervical cancer deaths in the five-year observation window is zero.
That is not the same as saying cervical cancer has been eliminated in England. Follow-up is still short. The cohort has not yet fully entered the decade of highest cervical cancer risk. And the comparison relies on historical controls, not a randomised design. Sasieni and colleagues acknowledge all of this.
What the data do show — and what cannot be discounted — is that population-level HPV vaccination at 88–90% coverage over sustained years translates into a mortality signal so attenuated that no deaths were observed. In epidemiology, absence of events in adequately followed populations is evidence. It is not proof of permanent elimination, but it is evidence of profound suppression.
The caveats that matter most. The zero-death finding applies to women vaccinated with the original bivalent Cervarix vaccine, which targets HPV-16 and HPV-18. Approximately 30% of cervical cancers are caused by other HPV types not covered by that vaccine. England switched to the nonavalent Gardasil 9 during the 2021–22 academic year, which covers seven additional oncogenic types relative to the original bivalent Cervarix (HPV types 6, 11, 31, 33, 45, 52, and 58, on top of HPV-16 and 18) — or five additional types relative to the quadrivalent Gardasil that England used from 2012 to 2021. The mortality benefit in subsequent cohorts — those receiving the wider-spectrum vaccine — will not be measurable for another decade, but is expected to be larger.
The catch-up cohorts (80% mortality reduction) and the 25–29 age group (69% reduction) show a gradient: the earlier the vaccine was received, relative to sexual debut, the greater the protection. This is not surprising — it is the biological expectation of a vaccine that prevents infection before it establishes. But it confirms that catch-up vaccination in older adolescents and young adults delivers meaningful but attenuated benefit.
What is not known yet. Whether the zero-death signal will hold as the cohort enters its forties, when cervical cancer incidence historically peaks. Whether the transition to Gardasil 9 will widen the gap further. Whether England’s high-coverage programme is generalisable to countries with weaker school-based delivery or lower baseline screening uptake.
The policy implication is not subtle. England reached 88–90% coverage through a funded, school-based opt-in programme that requires parental (or Gillick-competent self) consent — the high coverage reflects sustained voluntary uptake, not mandated attendance — maintained over fifteen years. Countries without that infrastructure should not read the England result as an argument for complacency; they should read it as a target.
Correction (2026-06-19): Two errors corrected by post-publication fact-check. (1) This editorial described England’s HPV programme as a “compulsory-attendance school programme”; the programme is opt-in and consent-based — vaccination is not mandated and the high coverage reflects voluntary uptake. (2) Gardasil 9 was said to cover “five additional oncogenic types” immediately after referencing the bivalent Cervarix; relative to Cervarix, Gardasil 9 covers seven additional HPV types. The “five additional” count is correct only relative to the quadrivalent Gardasil used in England from 2012 to 2021, which the editorial did not mention.